Annals of translational medicine | 2019

Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population.



Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no further episodes was recorded.

Volume 7 3
Pages \n 54\n
DOI 10.21037/atm.2019.01.02
Language English
Journal Annals of translational medicine

Full Text